Lymphoma treatment is continually evolving and improving the focus on precision medicine. The FDA has recently approved mosunetuzumab-axgb (Lunsumio) as “a bispecific CD20-directed CD3 T-cell engager for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.”
Mosunetuzumab-axgb is a first-of-its-kind bispecific antibody available to treat follicular lymphoma. “It is designed to attach to CD3, a protein on the surface of T-cells (a type of white blood cell) and CD20, a protein on the surface of B cells. This dual binding process is thought to bring your T cells close enough to engage with and release a type of protein called cytokines to kill cancerous B cells.”
Targeted therapy drugs are used to identify and eliminate cancer cells. Identifying a specific protein or genetic mutation enables a more efficient treatment. Monoclonal antibodies are laboratory-made proteins that attach to follicular lymphoma cells. Mosunetuzumab is designated as a monoclonal antibody.
An open-label, multicenter study was done with relapsed/refractory FL patients. These are the main outcomes:
Cycle 1: Day 1 - 1mg/ Day 8 - 2mg/ Day 15 - 60mg
Cycle 2: Day 1 - 60mg
Subsequent cycles: Day 1 - 30mg
A treatment cycle lasts 21 days and 8 cycles of mosunetuzumab are recommended. Patients can receive up to 17 cycles.
Mosunetuzumab treatment can cause Cytokine Release Syndrome (CRS). This is a severe side effect that can be life-threatening. Because of this risk, patients will receive medications to reduce the possibility of CRS between Cycle 1 and Cycle 2. Any of the following may indicate CRS:
During your regular treatment schedule, you may experience these possible side effects:
Read HERE for further information on clinical trial results.
Lymphoma treatment is continually evolving and improving the focus on precision medicine. The FDA has recently approved mosunetuzumab-axgb (Lunsumio) as “a bispecific CD20-directed CD3 T-cell engager for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.”
Mosunetuzumab-axgb is a first-of-its-kind bispecific antibody available to treat follicular lymphoma. “It is designed to attach to CD3, a protein on the surface of T-cells (a type of white blood cell) and CD20, a protein on the surface of B cells. This dual binding process is thought to bring your T cells close enough to engage with and release a type of protein called cytokines to kill cancerous B cells.”
Targeted therapy drugs are used to identify and eliminate cancer cells. Identifying a specific protein or genetic mutation enables a more efficient treatment. Monoclonal antibodies are laboratory-made proteins that attach to follicular lymphoma cells. Mosunetuzumab is designated as a monoclonal antibody.
An open-label, multicenter study was done with relapsed/refractory FL patients. These are the main outcomes:
Cycle 1: Day 1 - 1mg/ Day 8 - 2mg/ Day 15 - 60mg
Cycle 2: Day 1 - 60mg
Subsequent cycles: Day 1 - 30mg
A treatment cycle lasts 21 days and 8 cycles of mosunetuzumab are recommended. Patients can receive up to 17 cycles.
Mosunetuzumab treatment can cause Cytokine Release Syndrome (CRS). This is a severe side effect that can be life-threatening. Because of this risk, patients will receive medications to reduce the possibility of CRS between Cycle 1 and Cycle 2. Any of the following may indicate CRS:
During your regular treatment schedule, you may experience these possible side effects:
Read HERE for further information on clinical trial results.
about the author
Lisa Foster
Lisa Foster is a mom of 3 daughters, a puzzle lover, writer and HealthTree advocate. She believes in the mission of the foundation and the team that builds it forward. She calls Houston, Texas home.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.